Valuation — not yet established
No valuation for Medsyn Biopharma is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($19.6M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Medsyn Biopharma
Create free account
No card required
Funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Oct 2025 | Early Stage VC | $11.5M | ▮ | ▮ |
| Jul 2024 | Early Stage VC | $5.0M | ▮ | ▮ |
How Medsyn Biopharma's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Medsyn Biopharma, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Medsyn Biopharma raised?
- Medsyn Biopharma has raised $19.6M in total funding across 2 recorded rounds.
- When did Medsyn Biopharma last raise?
- Medsyn Biopharma last raised in Oct 2025 (Early Stage VC), raising $11.5M.